drugset

drugset / Trial / NCT02265679

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

NCT02265679 ↗

Phase 1 Completed 45 enrolled Boehringer Ingelheim

RandomizedParallel-groupDouble-blindTreatment

Summary

Safety, tolerability and pharmacokinetics following single doses

Timeline

Start: 2001-10
Primary completion: 2002-07
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMELUBANT	Small molecule	—	Oral

Indications